Products rMenB+OMV NZ
rMenB+OMV NZ Phase 3 Completed 📈 Rising Prevention of the Meningococcal Disease
Prevention of the Meningococcal Disease
Aug 1, 2013 → Apr 1, 2014
About rMenB+OMV NZ rMenB+OMV NZ is a phase 3 stage product being developed by Novartis for Prevention of the Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01911221. Target conditions include Prevention of the Meningococcal Disease.
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT01911221 Phase 3 Completed Aug 1, 2013 Apr 1, 2014 Prevention of the Meningococcal Disease NCT01139021 Phase 3 Completed Jun 1, 2010 Sep 1, 2011 Meningococcal Disease
Competing Products 20 competing products in Prevention of the Meningococcal Disease
See all competitors Product Company Stage Hype Score edoxaban + enoxaparin sodium Daiichi Sankyo Phase 3 Mifepristone Eli Lilly Phase 2 EXANTA AstraZeneca Phase 2 Risk of low dose aspirin discontinuation AstraZeneca Pre-clinical DAPA/MET XR + DAPA + MET XR AstraZeneca Phase 3 Esomeprazole + Placebo AstraZeneca Phase 3 PCV15 Merck Pre-clinical Raltegravir Merck Approved RotaTeq (V260) + IPV Merck Phase 3 V501 Merck Phase 3 Zostavax Merck Phase 3 V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 Merck Phase 3 Letermovir + Placebo Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Enteric-coated mycophenolate sodium Novartis Phase 3 Meningococcal C conjugate vaccine Novartis Approved Enteric-Coated Mycophenolate Sodium Novartis Phase 3 Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml Novartis Phase 3 Meningococcal C Conjugate Vaccine Novartis Phase 3 MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine) Novartis Phase 2
Other Products from Novartis